MGX (Metagenomi) Debt-to-Asset : 0.14 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Metagenomi Debt-to-Asset?

Metagenomi's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $5.59 Mil. Metagenomi's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $40.19 Mil. Metagenomi's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $324.60 Mil. Metagenomi's debt to asset for the quarter that ended in Dec. 2024 was 0.14.

Metagenomi Debt-to-Asset Historical Data

The historical data trend for Metagenomi's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Metagenomi Debt-to-Asset Chart

Metagenomi Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

0.35

0.05

0.13

0.14

Metagenomi Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial						0.13	0.12	0.12	0.13	0.14

Competitive Comparison of Metagenomi's Debt-to-Asset

For the Biotechnology subindustry, Metagenomi's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metagenomi's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Metagenomi's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Metagenomi Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Metagenomi's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.592	+	40.186)	/	324.599
	=	0.14

Metagenomi's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5.592	+	40.186)	/	324.599
	=	0.14

Metagenomi (NAS:MGX) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Metagenomi Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Metagenomi's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Metagenomi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Metagenomi Inc (NAS:MGX) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

5959 Horton Street, Emeryville, CA, USA, 94608

Website

https://www.metagenomi.co

Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. Genetic diseases are caused by a diverse set of mutations that have been largely inaccessible by genome engineering approaches to date. The genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems (including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs).